ICLE 2022 | Utilizing neoantigen-specific TCRs for personalized immunotherapies
Angela Krackhard
• 6 Apr 2022
Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, discusses her research on neoantigen-specific T cell receptors (TCRs) in advancing personalized treatments for cancer. Deep sequencing analysis of tumor DNA and RNA as well as mass spectrometry have confirmed the existence of various neoantigens on tumors detectable by T-cells. Variations of T-cell receptors were identified, where they have a lower activation threshold, resulting in lower PD-1 expression and less exhaustion. Prof. Krackhard additionally highlights the clinical potential of these TCRs as a result of their longer activation potential. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
